The first volunteers in the early-stage trial were given their first injections on Wednesday, Pfizer spokesperson Sharon Castillo said.
Inc and German partner BioNTech
SE began testing their COVID
in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said on Thursday.
The first volunteers in the early-stage trial were given their first injections on Wednesday, Pfizer
spokesperson Sharon Castillo said.
was authorized by U.S. regulators in late December for people age 16 and older. Nearly 66 million doses of the vaccine
had been administered in the United States as of Wednesday morning, according to data from the U.S. Centers for Disease Control and Prevention.
The pediatric trial, which will include children as young as 6 months, follows a similar one launched by Moderna Inc last week.
Only the Pfizer
is being used in 16- and 17-year-olds in the United States. Moderna's shot was cleared for those age 18 and older, and no COVID
has been authorized in younger kids yet.
plan to initially test the safety of their two-shot vaccine
at three different dosages - 10, 20 and 30 micrograms - in a 144-participant Phase I/II trial.
They plan to later expand to a 4,500-participant late-stage trial in which they will test the safety, tolerability and immune response generated by the vaccine
, likely by measuring antibody levels in the young subjects.
Castillo said the companies hope to have data from the trial in the second half of 2021.
has been testing the vaccine
in children from age 12 to 15. The company expects to have data from that trial in the coming weeks, Castillo said.